

ONXEO

Corporation with a Board of Directors (Société Anonyme à Conseil d'Administration)
with a share capital of 22,998,733.75 euros

Headquarters: 49 boulevard du Général Martial Valin, 75015 Paris
TCR 410 910 095 Paris

LIST OF THE BOARD MEMBERS

POSITIONS HELD IN OTHER COMPANIES

General meeting of April 19, 2022

Independent Director	Offices and functions
<p>Shefali AGARWAL</p> <p>Dr. Shefali Agarwal has been an independent director since June 10, 2021 and was appointed as chairperson of the Company on July 29, 2021. Her term of office will expire at the 2024 General Assembly.</p> <p>Born on September 27, 1973, Dr. Shefali Agarwal, who is a physician by training, is the Medical and Development Director at Epizyme, Inc., a developer of novel epigenetic therapies for cancer and other serious diseases, where she leads global clinical development and regulatory strategy. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions including clinical development and operations, and medical and regulatory affairs. In particular, she led the clinical development and registration of the PARP inhibitor ZEJULA® (niraparib) in ovarian cancer for Tesaro.</p>	<p><u>In the Company</u></p> <ul style="list-style-type: none">• Chairwoman of the Board of Directors <p><u>Outside the Company</u></p> <ul style="list-style-type: none">• EVP Chief Medical and Development Officer of Epizyme• Member of the Board of Directors of ITB Med• Member of the Board of Directors of Gritstone Bio• Member of the Board of Directors of Fate Therapeutics <p><u>Other offices and positions held over the past five years and completed</u></p> <ul style="list-style-type: none">• Lead GYN Oncology Advisor of Tesaro, Inc.• Non-executive advisor of SQZ Biotechnologies
<p>Danièle GUYOT-CAPARROS</p> <p>Danièle Guyot-Caparros has been an independent director of Onxeo since June 26, 2013 and chaired the Company's Board of Directors between May 2019 and July 2021. Her term of office will expire at the 2022 Shareholders' Meeting.</p> <p>Danièle Guyot-Caparros was born on October 16, 1958. After working in an audit firm on international assignments, she joined Rhône-Poulenc, which became Aventis and then Sanofi, in various positions of increasing scope, with responsibilities in finance at the European level and then in Business Planning and Performance Monitoring at the global level. Senior Life Sciences advisor for Deloitte since 2008, she holds a Master's degree in Finance/Accounting as well as a DECF (chartered accountant diploma).</p>	<p><u>In the Company</u></p> <ul style="list-style-type: none">• Director <p><u>Outside the Company</u></p> <p>None</p> <p><u>Other offices and positions held over the past five years and completed</u></p> <ul style="list-style-type: none">• Senior Advisor Life Sciences & Health Care Deloitte France• Member of the Supervisory Board of Diaxonhit• Director of Supersonic Imagine SA

Director	Offices and functions
<p>Judith GRECIET</p> <p>Judith Greciet joined Onxeo on March 1, 2011 as Deputy CEO in charge of R&D and Operations and served as CEO from June 29, 2011 to January 3, 2022.</p> <p>She has been a director of Onxeo since June 29, 2011. Her term of office will expire at the 2023 Shareholders' Meeting.</p> <p>Born on October 27, 1968, Judith Greciet has spent her career in various international laboratories (notably Eisai, Zeneca, Wyeth) holding positions of increasing managerial and strategic importance in the fields of oncology and immunology, with innovative products. She is a doctor of pharmacy and has a post-graduate degree in pharmaceutical management and marketing.</p>	<p><u>In the Company</u></p> <ul style="list-style-type: none"> • Director <p><u>Outside the Company</u></p> <p>None</p> <p><u>Other offices and positions held over the past five years and completed</u></p> <ul style="list-style-type: none"> • Chief executive officer of Onxeo SA • Chairwoman of Onxeo US Inc. • Director of Topotarget UK
<p>FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA</p> <p>Financière de la Montagne has been a director since June 29, 2011. Its term of office will expire at the 2023 Shareholders' Meeting.</p> <p>Born on May 29, 1963, Nicolas Trebouta has been investing directly or through funds in biotech companies since 2004 through his Company Financière de la Montagne. Co-founder of Chevrillon et Associés in 2000, he participated in a number of LBOs with this structure, including Picard surgelés, the printing company CPI, and the insurance company Albingia. He is a physician and has been a shareholder of Onxeo since 2008.</p>	<p><u>In the Company</u></p> <ul style="list-style-type: none"> • Director <p><u>Outside the Company</u></p> <ul style="list-style-type: none"> • Manager of SARL Financière de la Montagne • Manager of SCI Fleurus Immobilier • Manager of SCI 5 rue de la Liberté • Chairman of SAS Dragon 8 • Managing partner of SC Financière des Associés • Director of GIE IO • Chairman of the Supervisory Board of SCA Chevrillon & Associés • Manager of EARL Ferme de Bissy • Managing partner of SC Valois • Manager of SCI du Trillon • Co-manager of SC Aster • Managing partner of SCI du Chardonnet <p><u>Other offices and positions held over the past five years and completed</u></p> <p>None</p>

Director	Offices and functions
<p>INVUS PUBLIC EQUITIES LP, represented by Julien Miara</p> <p>At its meeting on September 17, 2020, the Board of Directors of Onxeo decided to co-opt Invus Public Equities LP as a Director of the Company. This co-option has been approved at the Company's ordinary general meeting on June 11, 2021. Its term of office will expire at the Shareholders' Meeting in 2022.</p> <p>Onxeo has announced the appointment of Julien Miara as interim CEO, effective January 3, 2022, following the decision of the Board of Directors.</p> <p>Born on June 15, 1983, Julien Miara is a Director at Invus, which he joined in 2010 as an analyst for the investment activity in listed companies (Invus Public Equities LP), particularly covering biotechnologies. In 2018, he was promoted to lead the team in Europe. Previously, he worked in investment banking at BNP Paribas in Paris, Société Générale in New York, and in consulting.</p> <p>Julien Miara obtained his Master's degree in Management from EDHEC Business School in Lille (France) in 2009.</p>	<p><u>In the Company</u></p> <ul style="list-style-type: none"> • Director <p><u>Outside the Company</u></p> <p>None</p> <p><u>Other offices and positions held over the past five years and completed</u></p> <p>None</p>
<p>Bryan GIRAUDO</p> <p>Bryan Giraudo has served as an independent director since November 23, 2021. His term of office will expire at the 2024 Shareholders' Meeting.</p> <p>Bryan Giraudo was born on May 3, 1975. Bryan Giraudo is both Chief Operating Officer and Chief Financial Officer of Gossamer Bio, a U.S. listed biopharmaceutical company (Nasdaq: GOSS) which specializes in the development and commercialization of innovative therapies in the fields of immunology, inflammation and oncology. Previously, he was a Senior Managing Director at LEERINK Partners, where he was responsible for the life sciences investment banking business for the West Coast of North America and Asia. Prior to joining LEERINK Partners in 2009, Mr. Giraudo was a Managing Director in the Global Healthcare Investment Banking division at Merrill Lynch.</p>	<p><u>In the Company</u></p> <ul style="list-style-type: none"> • Director <p><u>Outside the Company</u></p> <ul style="list-style-type: none"> • Chief Operating Officer and Chief Financial Officer of Gossamer Bio Inc • Director of Protagonist Therapeutics <p><u>Other offices and positions held over the past five years and completed</u></p> <ul style="list-style-type: none"> • Senior Managing Director at Leerink Partners

Director	Offices and functions
<p>Robert L. COLEMAN</p> <p>At its meeting on October 6, 2021, the Board of Directors of Onxeo decided to co-opt Robert L. Coleman as an independent director of the Company. This cooptation will be submitted to the shareholders for approval at the Company's next ordinary general meeting.</p> <p>Dr. Coleman, born November 3, 1961, is the Scientific Director of the US Oncology Network, one of the largest U.S. networks dedicated to cutting-edge oncology care and research, with more than 400 ongoing clinical trials and over 1,400 physicians. Prior to joining US Oncology Network in 2020, Dr. Coleman was executive director of the MD Anderson Group Cancer Network Research Program. He was also a professor and the Ann Rife Cox Chair in Gynecology at the University of Texas. Dr. Coleman's work has been published in over 500 publications that focus on the role of novel therapies in ovarian cancer, such as the integration of PARP inhibitors into the treatment strategy.</p>	<p><u><i>In the Company</i></u></p> <ul style="list-style-type: none"> • Director <p><u><i>Outside the Company</i></u></p> <ul style="list-style-type: none"> • SVP and Chief Scientific Officer, US Oncology Research • Co-Director, GOG-Partners of the GOG Foundation, Inc <p><u><i>Other offices and positions held over the past five years and completed</i></u></p> <ul style="list-style-type: none"> • Executive Director of the MD Anderson Group Cancer Network Research Program
<p>GAMMAX CORPORATE ADVISORY, represented by Mr. Jacques Mallet</p> <p>At its meeting on October 6, 2021, the Board of Directors of Onxeo decided to co-opt GammaX Corporate Advisory, which is represented by Jacques Mallet, as an independent director of the Company. This cooptation will be submitted to the shareholders for approval at the Company's next ordinary general meeting.</p> <p>Dr. Jacques Mallet, born April 27, 1960, was Senior Vice President - Head of Analytics/Corporate Strategy and a member of the Executive Leadership Team at Sanofi and is currently a member of the Board of Directors of several public and private companies in the health technology sector. Previously, Mr. Mallet was head of investments at Auriga Partners, a leading private equity firm that specializes in life sciences in France, and has held senior positions at international consulting firms such as Monitor Deloitte and Accenture.</p>	<p><u><i>In the Company</i></u></p> <ul style="list-style-type: none"> • Director <p><u><i>Outside the Company</i></u></p> <ul style="list-style-type: none"> • Chairman of Gamma-X Corporate Advisory • Director of Technoflex • Director of the Fournier Majoie Foundation <p><u><i>Other offices and positions held over the past five years and completed</i></u></p> <ul style="list-style-type: none"> • Senior Vice President Portfolio Analytics & Corporate Strategy at Sanofi • Director of Isocell